Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8697314 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2ADORA2BMAPK1RXFP1 | |
| SCHEMBL8696549 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2ADORA2BMAPK1RXFP1 | |
| SCHEMBL10858566 | 0.96 | LMNA (0.73) | LMNASMN1; SMN2ADORA2BMAPK1RXFP1 | |
| SCHEMBL11611843 | 0.88 | LMNA (0.56) | LMNASMN1; SMN2ADORA2BMAPK1RXFP1 | |
| SCHEMBL16120975 | 0.87 | ADORA2B (0.88) | LMNASMN1; SMN2ADORA2BMAPK1RXFP1 | |
| SCHEMBL10811332 | 0.87 | LMNA (0.73) | LMNASMN1; SMN2ADORA2BMAPK1RXFP1 | |
| SCHEMBL4345194 | 0.87 | PDE4A (0.64) | LMNASMN1; SMN2ADORA2BMAPK1RXFP1 | |
| SCHEMBL11612265 | 0.87 | PDE4A (0.64) | LMNASMN1; SMN2ADORA2BMAPK1RXFP1 | |
| SCHEMBL2922888 | 0.87 | LMNA (0.57) | LMNASMN1; SMN2ADORA2BMAPK1RXFP1 | |
| SCHEMBL6774762 | 0.86 | LMNA (0.71) | LMNASMN1; SMN2ADORA2BMAPK1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0564461-B1 | THE USE OF ANTIBODIES TO TNF OR FRAGMENTS DERIVED THEREOF AND XANTHINE DERIVATIVES FOR COMBINATION THERAPY AND COMPOSITIONS THEREFOR | CELLTECH THERAPEUTICS LTD (GB) | 1997-01-02 | — | — | EP | claimed |
| EP-0305743-B1 | PHARMACEUTICAL MIXTURE PREPARATION, ITS MANUFACTURE AND USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-11-04 | — | — | EP | claimed |
| US-5118500-A | Side effect reduction when administering a xanthine derivative | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-06-02 | — | — | US | claimed |
| WO-1992007585-A1 | THE USE OF ANTIBODIES TO TNF OR FRAGMENTS DERIVED THEREOF AND XANTHINE DERIVATIVES FOR COMBINATION THERAPY AND COMPOSITIONS THEREFOR | CELLTECH LIMITED (GB) | 1992-05-14 | — | — | WO | claimed |
| EP-0462506-A1 | Pharmaceutical preparations of mixtures comprising cefotaxim and derivatives of xanthine and their use | Schrinner, Elmar J., Dr. (DE) | 1991-12-27 | — | — | EP | claimed |
| CN-1014024-B | PROCESS FOR PREPARING PHARMACEUTICALS-FORMULATION | HOECHST AG (DE) | 1991-09-25 | — | — | CN | claimed |
| EP-0169466-B1 | MIXTURE OF XANTHIN DERIVATIVES AND O-ACETYL-SALICYLIC ACID, OR THEIR PHARMACOLOGICALLY ACCEPTABLE SALTS, AND ITS USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-04-04 | — | — | EP | claimed |
| US-4880791-A | BLOOD DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-11-14 | — | — | US | claimed |
| EP-0305743-A2 | Pharmaceutical mixture preparation, its manufacture and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-03-08 | — | — | EP | claimed |
| CN-85106465-A | A kind of preparation process of pharmaceutical preparation | — | 1986-10-29 | — | — | CN | claimed |
| EP-0169466-A2 | Mixture of xanthin derivatives and O-acetyl-salicylic acid, or their pharmacologically acceptable salts, and its use | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-01-29 | — | — | EP | claimed |
| US-4515795-A | INSUFFICIENCY OF CEREBRAL BLOOD FLOW | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-05-07 | — | — | US | claimed |
| US-4189469-A | Pharmaceutical compositions | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | claimed |
| US-20120202846-A1 | MOLECULAR TARGET OF NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2012-08-09 | — | — | US | disclosed |
| US-20100204251-A1 | MOLECULAR TARGET OF NEUROTOXICITY | EXONHIT THERAPEUTICS SA (FR) | 2010-08-12 | — | — | US | disclosed |
| EP-1982704-B1 | New molecular target of neurotoxicity | EXONHIT THERAPEUTICS SA (FR) | 2010-08-04 | — | — | EP | disclosed |
| US-4542011-A | PROTECTIVE COATINGS | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-09-17 | — | — | US | disclosed |
| US-4515795-A | INSUFFICIENCY OF CEREBRAL BLOOD FLOW | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-05-07 | — | — | US | disclosed |
| US-4207321-A | PROMOTES BLOOD PERFUSION | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-06-10 | — | — | US | disclosed |
| US-4189469-A | Pharmaceutical compositions | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202846-A1 | MOLECULAR TARGET OF NEUROTOXICITY | PDE4B, TDP2, PDE4A | LMNA 355/4885SMN1; SMN2 4/4885ADORA2B 818/4885 |
| US-20100204251-A1 | MOLECULAR TARGET OF NEUROTOXICITY | PDE4B, TDP2, PDE4A | LMNA 355/4885SMN1; SMN2 4/4885ADORA2B 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.